Boston Partners Acquires 223,816 Shares of Enovis Co. (NYSE:ENOV)

Boston Partners boosted its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 27.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,048,532 shares of the company's stock after purchasing an additional 223,816 shares during the quarter. Boston Partners owned about 1.84% of Enovis worth $46,034,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. UMB Bank n.a. grew its position in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after purchasing an additional 300 shares in the last quarter. FMR LLC raised its stake in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. XTX Topco Ltd bought a new position in Enovis in the third quarter worth $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new stake in Enovis during the fourth quarter worth $228,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Price Performance

ENOV stock traded up $0.93 during trading on Monday, hitting $40.01. The company had a trading volume of 558,415 shares, compared to its average volume of 672,455. The company has a fifty day moving average price of $42.72 and a two-hundred day moving average price of $43.50. Enovis Co. has a fifty-two week low of $35.14 and a fifty-two week high of $62.79. The company has a market cap of $2.28 billion, a P/E ratio of -18.27 and a beta of 2.05. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Remove Ads

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC dropped their price objective on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 27th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.